Bipolar Disorder Daily News Blog

Abilify Approved for Bipolar Type 1

Bristol-Myers Squibb has announced that Aripiprazole (Abilify) tablets and oral solution, an antipsychotic indicated for the treatment of schizophrenia, acute mania and mixed episodes associated with bipolar disorder, has been approved for use in patients with Bipolar I Disorder with a recent manic or mixed episode who have been stabilized and maintained for at least 6 weeks. This most recent approval is based on the positive results of a randomized, placebo-controlled study in 161 patients, in which those treated with aripiprazole relapsed significantly later than placebo-treated patients.